Verastem, Inc. (VSTM)
8.38
+0.27
(+3.33%)
USD |
NASDAQ |
Oct 09, 16:00
8.41
+0.03
(+0.36%)
After-Hours: 20:00
Verastem Net Income (Quarterly) : -34.67M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -34.67M |
| March 31, 2026 | -36.59M |
| December 31, 2025 | -32.92M |
| September 30, 2025 | -98.52M |
| June 30, 2025 | -25.93M |
| March 31, 2025 | -52.10M |
| December 31, 2024 | -64.55M |
| September 30, 2024 | -23.97M |
| June 30, 2024 | -8.256M |
| March 31, 2024 | -33.86M |
| December 31, 2023 | -27.37M |
| September 30, 2023 | -20.00M |
| June 30, 2023 | -24.28M |
| March 31, 2023 | -15.71M |
| December 31, 2022 | -16.81M |
| September 30, 2022 | -18.09M |
| June 30, 2022 | -21.95M |
| March 31, 2022 | -16.96M |
| December 31, 2021 | -16.48M |
| September 30, 2021 | -22.79M |
| June 30, 2021 | -16.90M |
| March 31, 2021 | -15.03M |
| December 31, 2020 | -19.86M |
| September 30, 2020 | 13.14M |
| June 30, 2020 | -23.01M |
| Date | Value |
|---|---|
| March 31, 2020 | -37.99M |
| December 31, 2019 | -38.77M |
| September 30, 2019 | -30.14M |
| June 30, 2019 | -42.19M |
| March 31, 2019 | -38.10M |
| December 31, 2018 | -11.35M |
| September 30, 2018 | -21.67M |
| June 30, 2018 | -18.37M |
| March 31, 2018 | -21.05M |
| December 31, 2017 | -18.24M |
| September 30, 2017 | -23.13M |
| June 30, 2017 | -13.44M |
| March 31, 2017 | -13.00M |
| December 31, 2016 | -11.66M |
| September 30, 2016 | -7.922M |
| June 30, 2016 | -8.569M |
| March 31, 2016 | -8.294M |
| December 31, 2015 | -11.86M |
| September 30, 2015 | -15.44M |
| June 30, 2015 | -15.38M |
| March 31, 2015 | -15.18M |
| December 31, 2014 | -13.95M |
| September 30, 2014 | -13.33M |
| June 30, 2014 | -13.02M |
| March 31, 2014 | -13.06M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| SELLAS Life Sciences Group, Inc. | -9.605M |
| AbbVie, Inc. | 3.604B |
| Dianthus Therapeutics, Inc. | -50.22M |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 40.08M |
| Total Expenses (Quarterly) | 74.75M |
| EPS Diluted (Quarterly) | -0.3463 |
| Enterprise Value | 706.21M |
| Gross Profit Margin (Quarterly) | 89.92% |
| Profit Margin (Quarterly) | -86.51% |
| Earnings Yield | -29.36% |
| Normalized Earnings Yield | -23.93 |